Dr. Mary L. Schmidt
Claim this profileUniversity of Illinois
Expert in Tumors
Expert in Brain Tumor
48 reported clinical trials
99 drugs studied
About Mary L. Schmidt
Education:
- Graduated from the University of Louisville School of Medicine.
- Completed Residency and Fellowship at Northwestern University.
Experience:
- Holds Board Certifications from the American Board of Pediatrics and the American Board of Hematology-Oncology.
- Specializes in Pediatric Hematology and Oncology with a focus on Hemangioma, palliative care, and vascular formations.
- Has over 30 years of experience practicing at UI Health (University of Illinois Hospital & Health Sciences System).
- Fluent in multiple languages, including Spanish.
Area of expertise
1Tumors
Global LeaderStage I
Stage IV
Stage II
2Brain Tumor
Global LeaderStage IV
Stage I
Stage II
Affiliated Hospitals
University Of Illinois
Clinical Trials Mary L. Schmidt is currently running
Genetic Testing-Directed Therapy
for Pediatric Cancer
This Pediatric MATCH screening and multi-sub-study phase II trial studies how well treatment that is directed by genetic testing works in pediatric patients with solid tumors, non-Hodgkin lymphomas, or histiocytic disorders that have progressed following at least one line of standard systemic therapy and/or for which no standard treatment exists that has been shown to prolong survival. Genetic tests look at the unique genetic material (genes) of patients' tumor cells. Patients with genetic changes or abnormalities (mutations) may benefit more from treatment which targets their tumor's particular genetic mutation, and may help doctors plan better treatment for patients with solid tumors or non-Hodgkin lymphomas.
Recruiting1 award Phase 214 criteria
Selumetinib vs. Chemotherapy
for Brain Cancer
This trial is comparing a new drug, selumetinib, with standard chemotherapy to treat patients with a specific type of brain tumor. The patients do not have a certain genetic mutation and are not affected by a genetic disorder. Selumetinib works by blocking enzymes needed for tumor growth, while the standard drugs kill or stop tumor cells from dividing.
Recruiting2 awards Phase 3
More about Mary L. Schmidt
Clinical Trial Related7 years of experience running clinical trials · Led 48 trials as a Principal Investigator · 22 Active Clinical TrialsTreatments Mary L. Schmidt has experience with
- Cyclophosphamide
- Radiation Therapy
- Etoposide
- Laboratory Biomarker Analysis
- Vincristine Sulfate
- Cytology Specimen Collection Procedure
Breakdown of trials Mary L. Schmidt has run
Tumors
Brain Tumor
Neuroblastoma
Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Mary L. Schmidt specialize in?
Mary L. Schmidt focuses on Tumors and Brain Tumor. In particular, much of their work with Tumors has involved Stage I patients, or patients who are Stage IV.
Is Mary L. Schmidt currently recruiting for clinical trials?
Yes, Mary L. Schmidt is currently recruiting for 16 clinical trials in Chicago Illinois. If you're interested in participating, you should apply.
Are there any treatments that Mary L. Schmidt has studied deeply?
Yes, Mary L. Schmidt has studied treatments such as Cyclophosphamide, Radiation Therapy, Etoposide.
What is the best way to schedule an appointment with Mary L. Schmidt?
Apply for one of the trials that Mary L. Schmidt is conducting.
What is the office address of Mary L. Schmidt?
The office of Mary L. Schmidt is located at: University of Illinois, Chicago, Illinois 60612 United States. This is the address for their practice at the University of Illinois.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.